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account. The objective of this study was to develop a strategy of
priorization based on the social welfare function (SWF), and to
apply this method to decide allocation of resources between
smoking cessation therapies and pharmacological treatments of
hypercholesterolemia. METHODS: The social welfare function
relates social welfare to the distribution of health gains between
two patient groups, where the exact form depends on parame-
ter e. The strategy of priorization based on SWF gives a higher
priority to treatments associated with values of e consistent with
that from the SWF. Parameter e of the SWF in Catalonia (Spain)
was determined using multiple logistic regression analysis to
assess preferences concerning the efﬁciency-equity trade-off in a
group of health managers (n = 140). RESULTS: The value of
parameter e obtained was 2.26 (95% CI: 1.07–2.89). This value
was consistent with a non-utilitarian SWF. Values of e obtained
for preventive interventions combining different smoking cessa-
tion methods for smokers and 20–80mg/day lovastatin for indi-
viduals with hypercholesterolemia ranged from 0 to 2.9 in men
and from 0 to 2.4 in women. The intervention using medical
advice for smoking cessation in smokers and 20mg/day lovas-
tatin in individuals with hypercholesterolemia was associated
with an e value of 2.9 in men and 2.4 in women, while inter-
ventions using nicotine substation therapies in smokers were
associated with values of e < 1.0 in men and <0.5 in women.
CONCLUSION: The strategy of priorization based on SWF
gives a higher priority to 20–80mg/day lovastatin for hypercho-
lesterolemia than to nicotine substitution therapies for smokers.
The strategy of priorization based on the SWF could give a
higher priority to new treatments reducing the difference in
health levels between groups of patients.
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OBJECTIVES: Whereas the market share held by generic drugs
exceeded 15% in Germany, UK, and Denmark in 2002, this
amounted to 4% in Belgium. This paper purports to review the
policy and regulatory environment surrounding generic drugs in
Belgium with a view to clarifying its low market share.
METHODS: The methodology is based on a literature review
and analysis of legal texts. RESULTS: The low market share held
by generic drugs in Belgium principally derives from the absence
of incentives for physicians to prescribe and for pharmacists to
dispense generic drugs. Although physicians are a major driver
of generic drug use through their prescribing behaviour, they
have no stake in the decision to prescribe original or generic
drugs, and are therefore not cost conscious. Moreover, multi-
plying the number of drugs containing the same active products
confuses the prescribing physician. Belgian pharmacists are not
allowed to substitute generic for original drugs and were, until
recently, ﬁnancially penalized for dispensing generic drugs. Addi-
tionally, marketing too many essentially similar drugs does not
encourage pharmacists to cooperate as their stock gets over-
loaded. Price regulation has stimulated generic drug use, as the
introduction of the reference-based pricing system in 2001 was
associated with an increase in market share of reimbursable
generic drugs by 3%. However, reference pricing also caused a
free fall of prices of original drugs by at least 16%, damaging
one of the driving forces of generic prescribing. CONCLU-
SIONS: If policy makers wish to stimulate generic drug use in
Belgium, they need to recognize the prime role that physicians
and pharmacists play in determining drug use and provide
appropriate incentives. Current initiatives that bring together
health professionals within local intercollegiate networks and
that promote the prescription of drugs using their International
Non-Proprietary Name need to be evaluated.
